Improving cardiovascular risk reduction for primary prevention-utility of lifetime risk assessment

Postgraduate Medicine

Volumn 122, Issue 4, 2010, Pages 192-199

  Elward, Kurt S ^a   Simpson Jr , Ross J ^b   Mendys, Phil ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

Cardiovascular disease; Lifetime risk; Literature review; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

AGING; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; EXERCISE; HEALTH CARE PRACTICE; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; LIFESTYLE MODIFICATION; PREDICTION; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SELF CONCEPT; SEX DIFFERENCE; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE;

CARDIOVASCULAR DISEASES; HUMANS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 77956641865     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.07.2186     Document Type: Review

References (42)

1. Erhardt L, Moller R, Puig JG. Comprehensive cardiovascular risk management-what does it mean in practice? Vasc Health Risk Manag. 2007;3(5):587-603.
2. World Health Organization. 2007. Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular Risk. NLM classification: WG 120; 92 pp. Geneva, Switzerland.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
5. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611-619.
6. Aarabi M, Jackson PR. Predicting coronary risk in UK South Asians: an adjustment method for Framingham-based tools. Eur J Cardiovasc Prev Rehabil. 2005;12(1):46-51.
7. Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis. 2006;184(1):201-206.
8. Karim R, Hodis HN, Detrano R, Liu CR, Liu CH, Mack WJ. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008;102(7):825-830.
9. Assmann G, Schulte H. The Prospective Cardiovascular Münster Study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol. 1987;59(14):9G-17G.
10. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2009;338(a3083).
11. Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med. 2008;149(10):751-760.
12. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):496-507.
13. Roberts EB, Ramnath R, Fallows S, Sykes K. "First-hit" heart attack risk calculators on the world wide web: implications for laypersons and healthcare practitioners. Int J Med Inform. 2008;77(6):405-412.
14. Singh M, Rihal CS, Lennon RJ, Spertus J, Rumsfeld JS, Holmes DR Jr. Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. Mayo Clin Proc. 2007;82(6):701-708.
15. Cavanaugh-Hussey MW, Berry JD, Lloyd-Jones DM. Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool. Prev Med. 2008;47(6):619-623.
16. Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet. 2008;371(9623):1547-1549.
17. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25(6):484-491.
18. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ. 1981;283(6285):179-186.
19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
20. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148(1):36-69.
21. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89(3):1333-1445.
22. The Scandinavian Simvastatin Survival Study (4S) Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
23. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
25. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
26. Ansell BJ. Evidence for a combined approach to the management of hypertension and dyslipidemia. Am J Hypertens. 2005;18(9 pt 1): 1249-1257.
27. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14(2):83-90.
28. Bhatt DL, Steg PG, Ohman EM, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-189.
29. Shephard RJ, Balady GJ. Exercise as cardiovascular therapy. Circulation. 1999;99(7):963-972.
30. Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, Bazzarre TL; Nutrition Committee Population Science Committee and Clinical Science Committee of the American Heart Association. AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. Circulation. 2001;103(13):1823-1825.
31. Mahoney EM, Wang K, Cohen DJ, et al; REACH Registry Investigators. One-year costs in patients with a history of or at risk for artherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1(1): 38-45.
32. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
33. Kostis JB, Breazna A, Deedwania PC, LaRosa JC. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. J Clin Hypertens (Greenwich). 2008;10(5):367-376.
34. Maron DJ, Boden WE, O'Rourke RA, et al; COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010;55(13):1348-1358.
35. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847-852.
36. Han JC, Lawlor DA, Kimm SY. Childhood obesity. Lancet. 2010;375(9727):1737-1748.
37. Leibson CL, Williamson DF, Melton LJ 3rd, et al. Temporal trends in BMI among adults with diabetes. Diabetes Care. 2001;24(9): 1584-1589.
38. Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes. 2010;3(1):8-14.
39. Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol. 2004;43(10):1791-1796.
40. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791-798.
41. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89-92.
42. Lloyd-Jones DM, Dyer AR, Wang R, Daviglus ML, Greenland P. Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry). Am J Cardiol. 2007;99(4):535-540.